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including an increased level of gamma-amino-butyrate and 
palmitoleic acid in males and a decreased level of entero-
lactone in females. Barley and oat derived BG were found 
to influence the human fecal metabolome differently. Bar-
ley BG increased the relative level of formate in males and 
isobutyrate, isovalerate, 2-methylbutyrate in females. In total 
15, 3 and 11 human fecal metabolites were significantly dif-
ferent between control vs. BG, control vs. oat BG, and barley 
BG vs. oat BG, respectively.
Conclusions The study show that human fecal metabo-
lome largely reflects individual (∼28% variation) and gender 
(∼15% variation) differences, whereas the treatment effect of 
the BG (∼8% variation) only manifests in a few key metabo-
lites (primarily by the metabolites: d-2-aminobutyric acid, 
palmitoleic acid, linoleic acid and 11-eicosenoic acid).
Keywords Mixed linkage β-glucan · Short chain fatty 
acids · Fecal metabolome (GC-MS) · Chemometrics · 
ASCA
1 Introduction
Mixed-linkage (1→3),(1→4)-β-d-Glucans (BG) have been 
investigated in in vivo and in vitro studies, for their func-
tional properties and health beneficial effects (Chen and 
Raymond 2008; Daou and Zhang 2012). BG are plant cell-
wall polysaccharides and have been proven to exert ben-
eficial effects in the gastro-intestinal tract (Cloetens et al. 
2012; Lam and Cheung 2013) due to their physicochemical 
properties in aqueous environment such as thickening and 
gelling agent (Izydorczyk and Biliaderis 2000). The reported 
bioactivities of BG include: (1) lowering of the post-prandial 
blood insulin and glucose levels (Battilana et al. 2001; Jen-
kins et al. 2002; Frank et al. 2004; Biorklund et al. 2005; 
Abstract 
Introduction Mixed-linkage (1→3),(1→4)-β-d-glucans 
(BG) reduce cholesterol level and insulin response in 
humans. Despite this, their role in human metabolism and a 
mode of action remains largely unknown.
Objectives To investigate the effects of three structurally 
different BG on human fecal metabolome in a full cross-over 
intervention using GC-MS metabolomics.
Methods Over three weeks of intervention, young healthy 
adults received food supplemented with BG from oat, two 
different BG from barley or a non-fiber control in a full 
cross-over design. Untargeted metabolomics and short chain 
fatty acid analysis was performed on day three fecal samples. 
ANOVA-simultaneous component analysis was applied to 
partition the data variation according to the study design, 
and PLS-DA was used to select most discriminative metabo-
lite markers.
Results Univariate and multivariate data analysis revealed 
a dominating effect of inter-individual variances followed by 
a gender effect. Weak effects of BG intake were identified 
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Beck et al. 2009a), (2) decrease of the cholesterol level in 
hypocholestorolaemic humans as well an in animals (Kalra 
and Jood 2000; Kerckhoffs et al. 2002; Delaney et al. 2003; 
Biörklund et al. 2005; Queenan et al. 2007), (3) reduction 
of blood pressure (Keenan et al. 2002; Liatis et al. 2009) 
and (4) increased cholecystokinin production (Bourdon et al. 
1999; Beck et al. 2009a). It has been hypothesized that the 
ingestion of large amount of BG can only induce modest 
alteration in human blood (Battilana et al. 2001).
Despite the rich literature about the health beneficial 
effects of BG, a number of studies have not been able to 
show significant effects of BG. Frank et al. (Frank et al. 
2004), investigated the effects of two oat-derived BG on 
blood lipids, glucose, insulin and tocopherol where BG 
showed no effect. Queenan et al. (2007) studied concentrated 
oat BG and observed that this soluble dietary fiber did not 
influence blood glucose and insulin concentration, weight, 
homocysteine and C-Reactive protein. Ibrügger et al. (2013) 
showed that BG do not lower a cholesterol level in young 
healthy adults after 3-weeks of BG consumption (3.3 g/day), 
and in a follow-up study Mikkelsen et al. (Mikkelsen et al. 
2014) showed no systematic metabolic differences between 
BG and control group using NMR metabolomics of blood 
plasma.
While the reasons for many no-effect studies may be 
multi-facetted, including lack of power and the use of inap-
propriate study design, the health beneficial potential of 
BG still calls for debate and the mechanisms are still under 
investigation. The health beneficial effects of BG have been 
related to their unique molecular block structures (Wood 
2007; Sullivan et al. 2013). The difference between the bar-
ley and oat BG relies primarily in their block ratio of cello-
triosyl and cellotetraosyl units connected by β-d-(1→3) link-
ages (Mikkelsen et al. 2013). This ratio is generally lower 
in oat than in barley and it is considered as an important 
molecular parameter of the BG (Hughes et al. 2008). This 
variation also depends on the specific plant genotype (Mik-
kelsen et al. 2013) and growing conditions (Herrera et al. 
2016). Oat BG have a higher water solubility than barley BG 
(Mikkelsen et al. 2013) and it is thus possible that BG from 
different sources with various structures and physicochemi-
cal properties may have a different impact on the metabolism 
of the host. Moreover, it has not been studied yet whether the 
effects of BG depend on the phenotype of the host.
This study investigates the same human intervention 
study as described in Ibrügger et al. (2013) and Mikkelsen 
et al. (2014). The study included three BG derived from 
oat, mother-line barley (BOMI) and a mutant barley (lys5.f) 
which were provided as supplements to low-fat yogurt or 
blackcurrant-syrup beverage and the same product was 
investigated without the addition of any BG as a control. 
While the previous two studies were focused on the blood 
metabolome, this study investigates effects of the BG on the 
fecal metabolome. It is hypothesized that the human fecal 
metabolome which is less influenced by homeostasis, may 
exhibit significant excretion effects related to the BG sup-
plement intake. The fecal metabolome has until recently not 
been scrutinized in great detail, but it represents a direct 
reflection of the crucial function of the gut and its microbiota 
to human health (Xu et al. 2014). Dietary fibers such as BG 
are known to be fermented by the microbiota into SCFA, 
which can be used by the mammalian host to produce the 
aforementioned beneficial effects. It is thus of fundamen-
tal interest to investigate whether the fecal metabolome is 
affected by the BG intake, and if so, how it is modulated by 
the different BG preparations. This study employs untargeted 
GC-MS metabolomics as well as GC-MS analysis of short-
chain fatty acids (SCFA) along with advanced multivariate 
data analysis in order to study possible effects of BG on the 
fecal metabolome in humans.
2  Materials and methods
2.1  Experimental design
The study design was single-blinded, randomized and 
4-armed cross-over and each treatment lasted 3 weeks and 
had at least 2 weeks of wash-out period (Fig. 1). The 16 
recruited subjects were normo-cholesterolaemic and fol-
lowed their normal dietary habits apart from a few restric-
tions (Ibrügger et al. 2013). The study was designed based 
on a power calculation (Kristensen et al. 2011, 2012) in 
order to assess total cholesterol differences with sufficient 
power and allowing a 10% drop-out rate. Fourteen subjects 
completed the study (eight females and six males). The 
experimental design is described in Fig. 1.
The oat BG were purified from a concentrate (Promoat™; 
Biovelop, Kimstad, Sweden) and barley BG were obtained 
either from a mother line BOMI (6% BG) or a mutant line 
lys5.f (16.5–19.8% BG) (Munck et al. 2004). The isolation 
of BG from grains was obtained by hot water and enzymatic 
hydrolysis, employing a modified procedure from Kvist and 
Lawther (Kvist and Lawther 2011), as described by Mik-
kelsen et al. (2013). The pre-hydrated BG preparations were 
given to the participants as a beverage with blackcurrant 
syrup  (Minimum®) or as a low-fat vanilla yoghurt (Arla 
 Cheasy®), with 1.65 g of BG per preparation, thus allowing 
the subjects to take the recommended daily dose of at least 
3 g of BG (21 CFR 101.81, 62 FR 3584, January 23 1997; 
EFSA Journal 2010).
2.2  Metadata collection
The diet of each participant was recorded for 4 days and 
entered into the Dankost 3000 dietary assessment software 
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(Dankost 3000, version 2.5; Danish Catering Center), in 
order to calculate the mean global intake of energy and 
macronutrients (carbohydrates, fats, proteins and alcohol) 
and fibers. Twenty-four blood parameters, including fasting 
concentrations of total, HDL and LDL cholesterol, plasma 
glucose and triacylglycerides were measured as reported by 
Mikkelsen et al. (2014).
Fecal samples were collected during 3 days, both before 
and after intervention (Fig. 1). Fecal samples of each par-
ticipant collected during the 3 days period were pooled and 
energy was measured using a bomb calorimeter (Ika-calo-
rimeter system C4000; Heitersheim). One sample from a 
participant, collected in one out of 3 days period, was used 
for pH measurement (PH-208; Lutron Electonic Enter-
prise) after being mixed with demineralized water (1:1) and 
homogenized. Further description of samples collection and 
analysis are reported elsewhere (Ibrügger et al. 2013; Mik-
kelsen et al. 2014). The final metadata variables consisted 
of blood parameters, anthropometric measurements [height, 
weight, age, body mass index (BMI)], dietary information 
(levels of hunger, satiety, fullness) and fecal parameters (e.g. 
pH, energy, weight, frequency).
2.3  GC-MS analysis
Untargeted GC-TOF-MS metabolomics of fecal slurry was 
performed on 1 ml fecal slurry which was mixed with 1 ml 
of a buffer followed by freeze dying and methanol extrac-
tion. Following a two step derivatization, methoximation 
and trimethylsilylation, the samples were analyzed using a 
HT Pegasus GC-TOF-MS system (LECO Corporation, Saint 
Joseph, USA). Targeted analysis of fecal SCFAs was per-
formed using 0.5 ml of fecal slurry, which was mixed with 
1 ml of 0.3 M oxalic acid and analyzed by GC-MS (Agilent 
Technologies, California, USA). The Detailed description of 
the GC-MS analysis is given in the Supplementary Material.
2.4  Data analysis
The data generated from the untargeted GC-TOF-MS 
metabolomics, targeted SCFA analysis, and metadata vari-
ables were analyzed individually as well as combined using 
univariate, including ANOVA, and multivariate, principal 
component analysis (PCA) (Hotelling 1933) and partial least 
squares-discriminant analysis (PLS-DA) (Ståhle and Wold 
1987), data analysis methods. According to the experimental 
design (Fig. 1), several factors including BG treatment (TR), 
gender (GN), and individual variations (IN), and their two 
and higher order interactions may contribute to a signifi-
cant variation. Subsequently, these variations may confound 
or interact with BG related metabolic changes. Therefore, 
ANOVA-simultaneous component analysis (ASCA) (Smilde 
et al. 2005) was performed for partitioning variations in the 
data into several effect matrices (e.g. XTR, XGN, XIN) using 
the study design. Subsequently each effect matrix was fur-
ther evaluated using PCA and PLS-DA as described in the 
previous study (Khakimov et al. 2016). PLS-DA based clas-
sification models, using variable selection, were developed 
for identification of metabolite markers related to the BG 
treatment, using delta metabolomics data, ΔX = XT1 − XT0, 
where XT0 is the measurement before the intervention 
started and XT1 is the measurement after the intervention. 
The GC-MS data were autoscaled before multivariate data 
analysis which was performed using Matlab (R2014b The 
Mathworks Inc.). Details about ANOVA and ASCA calcula-
tions are reported in the Supplementary Materials.
Fig. 1  Design of experiment. 
The trial is a randomized full 
cross-over, where the subjects 
undergo 3-weeks interventions 
of each treatment, followed by a 
2-weeks wash-out period. Fecal 
samples are collected during the 
3 days period before the treat-
ment started and during the last 
3 days period of each interven-
tion. The treatments consisted 
of: mother barley BG (a), oat 
BG (b), control (c) and mutant 
barley BG (d)
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3  Results and discussion
The untargeted GC-TOF-MS metabolomics data included 
279 variables that covered metabolite classes such as organic 
acids, carbohydrates, amino acids, and fatty acids. A total of 
164 out of 279 variables were identified at level 2, accord-
ing to the Metabolomics Standard Initiative (MSI) (Sumner 
et al. 2007). The SCFA data consisted of eight variables 
including acetic acid, formic acid, propionic acid, isobu-
tyric acid, butyric acid, isovaleric acid, 2-methylbutyric 
acid, valeric acid and one unknown compound. A total of 
44 metadata variables were used in this study. Table S1 in 
Supplementary Material contains a list of all the variables 
investigated in this study. The final size of the data was 105 
samples and 331 variables.
Initial PCA analysis of the ΔX and XT1, using all three 
datasets separately as well as combined dataset, showed no 
clear separation of individuals based on the BG treatment, 
but individual and gender related variations were more 
pronounced (Fig. S1 in Supplementary Material). In order 
to study the effects related to the study design, three main 
effects, TR, GN and IN, and their two-factor interaction 
effects were studied by ASCA using the ΔX and XT1 data-
sets. Variations derived from the study design were decom-
posed as following:
where X stands for either ΔX or XT1.
Due to the fact that GN is nested within IN, it is impos-
sible to evaluate all three factors simultaneously. Moreover, 
this study design does not allow to estimate IN and TR inter-
action term due to the consumption of degrees of freedom 
(Eq. 1). In order to evaluate TR and GN interaction terms 
using ASCA, the final dataset was balanced by removing 
four individuals where measurement time points were miss-
ing, which left 36 samples for the analysis. Both, ΔX and 
XT1 datasets were investigated using Equations 1 and 2 using 
the combined data from GC-TOF-MS, SCFA and metadata 
(Tables S2 and S3 in Supplementary Material).
Using the combined dataset, XT1 revealed significant 
(P = 1.8E−13) IN effect which explains 27.7% variation, 
while TR effect was not significant (P = 0.73) and explained 
6.6% variation. The IN effect was no longer significant 
(P = 0.64, 17.9% variation) when combined data was evalu-
ated using ΔX. Likewise, TR effect was also not significant 
(P = 0.78, 7.9% variation). A similar picture emerged when 
GC-TOF-MS data was evaluated for the IN and TR, using 
both ΔX and XT1 datasets. The SCFA data depicted large 
IN effect from XT1 (P = 1.49E−10) explaining 56.2% varia-
tion, though the TR effect remained not significant (P = 0.16, 
5.3% variation). However, the ΔX of the SCFA data showed 
(1)퐗 = 퐗퐌퐄퐀퐍+퐗퐈퐍+퐗퐓퐑+퐗퐑퐄퐒퐈퐃퐔퐀퐋퐒
(2)퐗 = 퐗퐌퐄퐀퐍+퐗퐓퐑+퐗퐆퐍+퐗퐓퐑×퐆퐍+퐗퐑퐄퐒퐈퐃퐔퐀퐋퐒
that the TR effect was on the border of being significant 
(P = 0.052) and explained the largest TR variation, 12.9%, 
when compared to the other datasets. Similar to the SCFA 
data, the metadata showed large IN effect (P = 1.0E−9, 
44.9% variation) from XT1 and a nearly significant TR effect 
(P = 0.063, 10.5% variation) when evaluated by ΔX.
The GN effect and its interaction with TR were evaluated 
according to the Eq. 2 using both the ΔX and XT1 data-
sets. The GN effect was significant from XT1 in all data-
sets including GC-TOF-MS (P = 0.02), SCFA (P = 2.47E-
4), metadata (P = 3.05E−7) and the combined dataset 
(P = 1.99E-4). The explained variances were 5.2, 22.1, 14.9, 
6.9%, respectively. The interaction term between GN and 
TR was not found to be significant in any cases.
The initial PCA and ASCA analysis suggests that the 
major variation on human fecal metabolome as well as on 
metadata were largely related to inter-individual and gender 
differences. However, a weak effect of BG treatment was 
observed in SCFA and metadata using ΔX. The sections 
below explore the GN effect in detail using XT1 and the TR 
effect using ΔX for the combined dataset. The effects will 
be further discussed on metabolite levels identified as being 
discriminant markers between males and females as well as 
for the different BG treatments.
3.1  Gender effect
A PCA model of the combined dataset using XT1, showed a 
gender related clustering amongst the participants (Fig. S1 
in Supplementary Material). This effect became even more 
pronounced on the PCA model developed on the gender 
effect separated matrix, XGN Eq. (2) using ASCA (Fig. 2).
In order to find the most discriminative variables sepa-
rating men from women, PLS-DA based variable selection 
was performed on the gender separated matrix, XGN, as 
described previously (Khakimov et al. 2016). PLS-DA mod-
els were validated using a double-check validation scheme as 
described in the literature (Szymanska et al. 2012). The final 
PLS-DA model, which included one principal component, 
possessed a high classification power with approximately 
19% misclassification rate using independent test set sam-
ples (30% of total samples). Identified metabolite markers 
from the PLS-DA based variable selection were further 
tested using a one-way ANOVA. Five out of 7 variables 
selected from the multivariate PLS-DA approach were also 
found to be significant in a univariate one-way ANOVA and 
they include diastolic pressure, body weight, energy intake, 
total ghrelin and ad libitum lunch (Fig. 2).
One of the gender metabolite markers was ghrelin which 
was higher in females compared to males. Ghrelin is a pep-
tide hormone formed by 28 amino-acids and it is secreted 
by endocrine cells in the stomach (Abu-Fahra et al. 2014). 
In a study on 24 non-diabetic adults focused on the effect 
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of different nutrient loads (glucose, protein and lipids) upon 
ghrelin levels, Greenman et al. (2004) found that ghrelin 
levels were significantly higher in females both at fasting 
state and after the glucose and lipid intervention. Gender-
related difference in total plasma ghrelin was also reported 
by Makovey et al. (2007), who measured it in opposite-
gender twins, and by Abu-Fahra et al. (2014), who inves-
tigated plasma ghrelin levels of 359 residents of Kuwait. 
The fact that there is significant difference in ghrelin levels 
between the two genders suggests that this factor could have 
an impact on the response to the intervention. In fact, ghrelin 
has been shown to stimulate appetite and release of corti-
sol, decrease energy metabolism and promote adipogenesis 
(Makovey et al. 2007). The levels of ghrelin in plasma are 
increased in fasted states and are lowered after meals (Mako-
vey et al. 2007). It is thus likely that ghrelin has an influence 
on metabolism and appetite in humans and therefore could 
cause different behavior and responses to the selected treat-
ment between males and females. Indeed, the administra-
tion of ghrelin to mice and rats has been shown to cause an 
increased food intake and weight gain (Tschöp et al. 2000).
3.2  Treatment-related effects
The initial hypothesis of this study was that the three struc-
turally different BG may exert slightly varying hypocho-
lesterolemic effects in humans. The previous study showed 
that oat BG had a great functional potential, with a greater 
decrease in fasting triacylglycerol, which might be due to 
physicochemical properties such as higher viscosity and 
solubility (Ibrügger et al. 2013). The consumption of oat 
and barley derived BG by young healthy adults showed no 
clear treatment-related effect when the plasma metabolome 
was investigated by NMR spectroscopy (Mikkelsen et al. 
2014). However, the study revealed the presence of subject-
dependent lipoprotein plasma profiles and variations due to 
gender, BMI and diet.
In this study, ASCA and PCA analysis performed on 
the ΔX showed a partial discrimination of the treatments, 
oat BG subjects were more different than others (data not 
shown). However, PCA of ΔX could not capture an effect of 
all BG groups. This may be due to a small treatment effect 
compared to the large inter-individual and gender variation. 
In order to reduce complexity, three different combinations: 
oat BG vs. control, oat BG vs. barley BG, and control vs. all 
types of BG, were studied in detail.
A previous study (Frank et al. 2004) showed that the 
intake of oat BG lowered cholesterol level in females more 
than in males, thus suggesting a modulation of the effect of 
BG intake depending on gender. In this study the effects of 
BG treatments were not always consistent for both genders 
(data not shown) and the effects were often more clear when 
one gender was studied at a time. Below we will describe 
effects of treatments separately for each gender.
3.2.1  Control vs. oat
The effect of the oat BG intake was mostly pronounced 
among males, where one particular variable, unknown 16, 
was able to discriminate oat BG group from a control group 
(Fig. 3). Few other variables were also consistently detected 
being markers for oat BG group, including females. Two 
metabolites were mostly responsible for this discrimination 
and they both decrease during the oat treatment. One of them 
is enterolactone. Further results are reported in Table 1 and 
the discussion is found in the Supplementary Material.
3.2.2  Control vs. BG
Evaluation of all types of BG treatment groups simultane-
ously against the control group using PLS-DA and ANOVA 
revealed 11 variables that were identified as markers for BG 
treatments in females. Most of the discriminative metabo-
lites decreased during the BG treatment including mannose 
and unknown 82 (Fig. 3). The decrease of sugars could be 
ascribed to the delay and decrease in starch metabolism and 
carbohydrate absorption due to the action of BG (Andrade 
et al. 2016).
In males, five variables were able to discriminate between 
the two groups, and among these gamma-amino-butyrate 
(GABA) was the most powerful marker which was increased 
in the BG groups (Fig. 3). However, a similar intervention 
study involving BG intake derived from a whole grain barley 
pasta have shown contradicting results where GABA level 
was decreased as a function of BG intake among elderly 
males and females (De Angelis et al. 2015). Palmitoleic 
acid level was elevated in the BG groups which is in agree-
ment with a previous study involving oat bran consumption 
(Gu et al. 2015). Moreover, we found that lipids including 
linoleic acid, 11-eicosenoic acid and 1,2-propanediol levels 
were decreased in the BG groups.
3.2.3  Barley vs. Oat
A total of eight variables were found to be different 
between female subjects who received either barley BG 
or oat BG. PLS-DA and ANOVA revealed that the levels 
of glycolic acid, 3-hydroxybutanoic acid and myo-ino-
sitol, together with the SCFA including isobutyric acid, 
isovaleric acid and 2-methylbutyric acid were higher in 
individuals receiving barley BG (Table 1). A high inter-
correlation of some SCFA suggests presence of a strong 
relation in their metabolism which is high likely to be 
influenced by the BG consumption (Fig. 4). In fact, the 
anaerobic intestinal microbiota ferment BG, after these 
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are digested into glucopyranosides, into SCFA (Topping 
and Clifton 2001). Likewise, in this study, De Angelis 
et al. (2015) also found increased level of isobutyric acid 
in fecal samples as a function of BG intake through a pasta 
meal in a 2-month intervention study involving 26 healthy 
subjects. In addition, Nilsson et al. (2008) found increased 
fecal concentrations of isobutyrate and isovalerate after 
a dietary supplementation of BG enriched oat bran in 25 
young healthy individuals.
In males, formic acid, total plasma SCFA and urea were 
increased during barley BG treatment, whilst the concentra-
tion of unknown 59, tentatively identified as sugar metabo-
lite, was decreased. In agreement with this study, Nilsson 
et al. (2008) reported a decreased level of fecal formic acid 
Table 1  Major discriminant variables reflecting BG treatment effects. The arrow indicates which of the two treatments showed an increase in 
relative levels of a marker variable
Untargeted GC-TOF-MS variables
Metabolite/Variable Comparison P-value
Males
 Unknown 16 Control vs. Oat ↑ 0.00550
 1,2-Propanediol-2TMS Control ↑ vs. BG 0.0399
 d-2-Aminobutyric acid-2-TMS Control vs. BG ↑ 0.0225
 Palmitoleic acid-1TMS Control vs. BG ↑ 0.0335
 Linoleic acid-1TMS Control ↑ vs. BG 0.0381
 11-Eicosenoic acid-1TMS Control ↑ vs. BG 0.0314
 Urea-2TMS Barley ↑ vs. Oat 0.0465
 Unknown 59 (sugar) Barley vs. Oat ↑ 0.0213
Females
 Enterolactone Control ↑ vs. Oat 0.0179
 Unknown 82 Control ↑ vs. Oat 0.0132
 Hexamethyldisilthiane Control ↑ vs. BG 0.00555
 Ethylene glycol-2TMS Control vs. BG ↑ 0.0491
 Mannose, 6-deoxy-2,3,4,5-tetrakis-O-(trimethylsilyl)-, L- Control ↑ vs. BG 0.0123
 Unknown 72 Control ↑ vs. BG 0.0236
 4-O-β-Galactopyranosyl-d-mannopyranose, octakis(trimethylsilyl) 
ether (isomer 2)
Control ↑ vs. BG 0.0058
 Unknown 79 Control ↑ vs. BG 0.0373
 Enterolactone Control ↑ vs. BG 0.0028
 Tetracosanoic acid-1TMS Control ↑ vs. BG 0.0434
 Unknown 82 Control ↑ vs. BG 0.0009
 Tocopherol-γ-tms-derivative Control ↑ vs. BG 0.0024
 Unknown 89 Control ↑ vs. BG 0.0042
 Glycolic acid-2TMS Barley ↑ vs. Oat 0.0077
 3-Hydroxybutanoic acid-2TMS Barley ↑ vs. Oat 0.0345
 Unknown 7 Barley ↑ vs. Oat 0.0160
 Unknown 37 Barley ↑ vs. Oat 0.0398
 Myo-Inositol-5TMS, bis(trimethylsilyl) phosphate Barley ↑ vs. Oat 0.0250
SCFA and metadata variables
Males
 Formic Acid Barley ↑ vs. Oat 0.0099
 Total plasma SCFA Barley ↑ vs. Oat 0.0324
 Subjective fullness Barley vs. Oat ↑ 0.0172
Females
 Isobutyrate Barley ↑ vs. Oat 0.0108
 IsoValerate Barley ↑ vs. Oat 0.0290
 2MethylButyrate Barley ↑ vs. Oat 0.0205
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after 4 weeks of an oat bran intervention involving 25 young 
healthy adults. A decrease in formic acid suggests that the 
level of this metabolite is largely reduced due to the barley 
BG intake, since it is continuously synthesized in colon dur-
ing a microbial fermentation. The subjective fullness was 
found to be higher as a result of the oat BG intervention 
which is in accordance with previously published studies 
(Juvonen et al. 2009; Vitaglione et al. 2009) and might be 
related to the generally higher solubility and viscosity of oat 
BG (Juvonen et al. 2009). The fact that subjective fullness 
appears as significant only for males, may be due to the dif-
ferent ghrelin values found between the two genders (see 
Sect. 3.1), as this hormone is directly related to food intake.
A previous study showed that oat BG improved satiety in 
both females and males and the actual food intake of a sec-
ond meal after a BG enriched meal was lower in males (Beck 
et al. 2009a). Conflicting results, though, are also present 
in literature: a review by Cloetens and colleagues presents 
31 studies on the effects of BG intake and among these 8 
showed no significant results in any measured parameters, 
whilst many others only had partial results (Cloetens et al. 
2012). Therefore, a debate around the weight control effect 
of BG enriched meals are still present since the effect can 
depend on the food item into which BG are added, the type 
of BG (Jenkins et al. 2002; Bjorklund et al. 2005) and maybe 
even this effect can be different in different subject groups.
3.3  Main treatment related results
This study has revealed relatively weak effects of BG intake 
when compared against the control group receiving a non-
fiber glucagel, although a stronger discrimination was found 
when the barley BG treatment was compared with the oat 
BG treatment. Moreover, the SCFA were found to be modu-
lated differently by oat and barley BG which in turn indicate 
that different BG can alter the anaerobic bacterial fermen-
tation and result in different metabolic profiles. SCFA are 
directly correlated to BG, since they originate from their 
metabolism by the gut microbiota (Fig. 5). Formate, which 
was found to be higher in males after the barley BG interven-
tion, is in fact one of the first product originating from BG 
gut degradation, deriving from the metabolism of pyruvate. 
The other SCFA found in different levels between oat and 
barley BG treatments, derive from later stages of pyruvate 
metabolism and transformation of butyrate.
The employed oat BG extract was more soluble than the 
barley counterparts and had a higher viscosity. These two 
factors of the oat BG makes it more effective towards the 
improvement of the wellbeing (Cloetens et al. 2012). How-
ever, only a weak effect was observed between oat and con-
trol treatments. The experienced weak effects can be related 
to different reasons. The investigated subjects were all young 
healthy adults with relatively fast metabolism and with no 
specific cholesterol or diet-related issues and this might be 
the reason why the intervention did not show specific effects 
in cholesterolaemia and related anthropometric and blood 
parameters. In fact, it has been observed before that the 
cholesterol-lowering property of BG was more pronounced 
in subjects with initially higher cholesterolaemia (Önning 
et al. 1999; Frank et al. 2004).
In addition, the number of subjects involved in this study 
was relatively small and a large part of the data variation was 
related to the gender and inter-individual differences. Most 
importantly, the dietary intervention was performed by the 
Fig. 2  Bi-plot showing PC1 vs. PC3 scores and loadings of the PCA 
model calculated on the gender effect separated data matrix, XGN. On 
the left, the colors represent the gender classes, whilst on the right, 
the same plot is colored according to the treatment. PC3 was cho-
sen instead of PC2 due to the fact that it showed better separation 
between the gender classes
 A. Trimigno et al.
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Fig. 3  Relative concentrations 
of major variables found to be 
discriminative for treatments, 
using ΔX data: a unknown 16 
for control vs. oat in males; b 
unknown 82 for control vs. BG 
in females; c GABA for control 
vs. BG in males and d subjec-
tive fullness for barley vs. oat 
in males
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addition of only the recommended daily dose of BG and 
only for a short period of time (3 weeks). Thus, in a group 
of healthy young people this may not be sufficient to show 
strong metabolic effects. This is supported by the fact that 
Nilsson et al. (2008) observed an increase in fecal SCFA 
only after 8 weeks of intervention on a healthy cohort. They 
hypothesized that the colonic microbiota is more stable in 
healthy subjects, thus a change in its composition requires 
more time. Moreover, they experience a decreased in car-
boxylic acid concentrations after 12 weeks of intervention, 
possibly due to an adaptation of the microbiota.
The relative low dose of BG, 3.3 g/day, corresponding to 
the FDA and EFSA health claim, might also influence the 
results. In fact, most of the interventions employed higher 
doses of BG (Mäkeläinen et al. 2007; Beck et al. 2009b; Lyly 
et al. 2010), especially when added as a supplement to other 
foods. However, even at higher doses, some studies have 
showed no effect of BG (Davy et al. 2002; Keogh et al. 2003; 
Beck et al. 2010). Major metabolic effects due to the BG 
intake in this study were more clearly manifested in some 
individuals, which indicate that the effect of BG might have 
a rather personalized function. Therefore the IN effect was 
found to be the most dominating. For all these reasons, fur-
ther studies with much larger cohorts are necessary to better 
investigate the fecal metabolome variation after BG inter-
vention. This should also allow to better estimate phenotypic 
and individual responses to BG supplements. In addition, 
a higher dose of BG and/or hypercholesterolemic subjects 
might be necessary to evaluate effects and the plausible dif-
ferences between the structurally different BG.
Moreover, the complexity of the metabolomics data 
and the fact that only a relatively scarce literature exists, 
especially for human studies and related to specific dietary 
intervention, made it difficult to assign many metabolites 
with confidence. The intricate interaction between food-
derived molecules, digestion and microbiota, generates a 
complex pattern of fecal metabolites that is not yet clearly 
defined, especially in interventions where fibers like BG are 
used and are fermented by the gut microflora. The gut micro-
biota is a very intricate and its mechanisms and regulations 
remain largely unknown. Variations in its composition and 
behavior can depend on many factors including diet and the 
ethnicity and genetic make-up of the subjects, which can 
have an influence on its composition (Escobar et al. 2014; 
Kwok et al. 2014; Maukonen and Saarela 2015). Therefore, 
differences between the studied population and the ones 
considered in previous research might be another reason 
for the discrepancies found, together with the strong inter-
individual effect. Thus, more controlled and carefully design 
intervention considering all is needed prior to reveal insights 
into the mode of action and functionality of BG in humans.
4  Conclusion
This study demonstrated relatively weak, but consistent met-
abolic effects in the human fecal metabolome as a function 
of structurally different BG supplement intake. The weak 
trends found in this study were well in agreement with the 
previous findings, which proved only slight tendencies dur-
ing the intervention and showed that inter-individual and 
gender-specific effects were more prominent. This under-
lines the fact that the efficacy of BG interventions depend 
on factors, such as the length of the intervention, the dose of 
employed BG supplements, the number of subjects, and per-
haps even other phenotypic characteristics. In females, the 
Fig. 4  Correlation between 
2-methyl butyrate and isobu-
tyrate using ΔX data, differenti-
ating the barley BG and oat BG 
groups among female subjects
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enterolactone level was decreased when subjects underwent 
to the BG intake, whilst in males, the GABA level increased 
after the same treatment. SCFA discriminated oat BG group 
and barley BG group subjects both for males and females. 
Barley BG increase specific SCFA levels in both genders, 
whilst oat BG seems to be more effective in subjective full-
ness in males. Changes observed in the SCFA profiles as 
a result of BG intake were in accordance with previously 
published studies and confirmed the function of in bacterial 
fermentation in the gut.
In conclusion, this study represents a step forward 
in the analytical pipeline towards new research with a 
larger and more diverse cohort and using a much longer 
intervention-time with time-dynamic fecal sampling. The 
chemometrics approaches employed here showed that it 
is necessary to investigate all the possible effects that may 
impact data, and to validate observed metabolic effects 
using independent test set samples. It should be empha-
sized that the present study represents a relative untargeted 
fecal metabolomics study and that it is possible that a more 
targeted approach towards, for example, bile acids and/or 
cholesterol metabolism can provide additional information.
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Fig. 5  Metabolic destiny of BG 
through fermentation by the gut 
microbiota. Glucopyranosides 
(Glcp) are metabolized into 
pyruvate, which in turn can 
be metabolized into to various 
other metabolites including 
SCFA. Metabolites in green are 
intermediate compounds, whilst 
metabolites in dark red are end 
products
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